Dr. Gottesdiener has been our Chief Executive Officer and a member of our Board of Directors since October 2011. He joined Rhythm after 16 years at Merck Research Laboratories. Dr. Gottesdiener joined Merck early clinical development in 1995, helping to transition compounds from the bench to the bedside and through to proof of concept. He held positions of increasing responsibility, eventually leading Merck’s early clinical development across all therapeutic areas from 2001 through early 2006. From 2006 to 2011, he was a leader of Merck’s late clinical development organization, first overseeing the development of Merck’s infectious diseases and vaccine products through pivotal trials, registration, and life cycle management, including Gardasil™ (HPV Vaccine), Rotateq™ (rotavirus vaccine), Zostavax™ (zoster vaccine), and Isentress™ (HIV integrase inhibitor), among others. In 2008, Dr. Gottesdiener was appointed Late Stage Therapeutic Group Leader, and in that role, led Merck’s late-stage clinical development efforts (from Phase 2 through patent expiry) across all therapeutic areas. After Merck’s merger with Schering Plough in 2009, he continued as co-head of late development. Dr. Gottesdiener serves on the board of Intercept. He received his BA from Harvard College and his MD from the University of Pennsylvania. He completed his residency and fellowship at the Brigham and Women’s Hospital, Beth Israel Medical Center, and Dana Farber Cancer Institute Children’s Hospital programs. After his fellowship, Dr. Gottesdiener did postdoctoral research in the laboratory of Dr. Jack Strominger at Dana Farber Cancer Institute working on the molecular immunology of the T-cell receptor. In 1986, he joined the faculty as an Assistant Professor at Columbia University, started an independent research laboratory with NIH RO-1 funding that focused on gene transcription, and was Associate Clinical Professor of Medicine at the time he left to join Merck in 1995.
Board Of Directors
This is a remarkable place where our people are focused on doing great science and great clinical work, as everyone here cares passionately about making a meaningful impact on the lives of our patients.